MFDS — authorised 3 September 1974
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Status: likely_approved
🇰🇷 Catapres-Tts-1 in South Korea
MFDS authorised Catapres-Tts-1 on 3 September 1974
Marketing authorisation
Catapres-Tts-1 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in South Korea
Frequently asked questions
Is Catapres-Tts-1 approved in South Korea?
Yes. MFDS authorised it on 3 September 1974.
Who is the marketing authorisation holder for Catapres-Tts-1 in South Korea?
BOEHRINGER INGELHEIM holds the South Korean marketing authorisation.